FDA
-
-
-
-
-
-
-
Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
-
-
-
-
-
-
-
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
-
-
-
-
-
-
-
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
-
-
-
-
-
-
-
Outlook Therapeutics completes $5 million stock offering
-
-
-
-
-
-
-
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
-
-
-
-
-
-
-
Outlook Therapeutics Announces Proposed Public Offering
-
-
-
-
-
-
-
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
-
330,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

